

## Elsevier : informations sur l'accord Lecture et publication 2024-2027

### Détail du parcours de publication auteur et des choix à opérer

<b>Principaux éditeurs/titres concernés</b>	Elsevier Complete Freedom Collection, Bibliothèque médicale française Masson
<b>Période</b>	2024-2027
<b>Frais de publications (APC)</b>	Pour un auteur de correspondance Rennes 2 (ou ESR) : publication sans frais dans 2 444 revues, pour les types d'articles éligibles
<b>Types d'articles</b>	Case Report, Data in Brief, Full-length Article, Micro-article, Original Software Publication, Practice Guideline, Protocol, Review Article, Replication Study, Short Communication, Short Survey, Video Article. <a href="#">Voir détail</a>
<b>Titres éligible libre accès immédiat sans frais et sans embargo</b>	2444 revues hybrides (sur abonnement avec quelques articles OA) ou full OA
<b>Revues exclues de l'accord</b>	<a href="#">81 titres</a> (titres Lancet, Cell Press, de certaines sociétés savantes)
<b>Licences</b>	CC-BY 4.0; CC-BY-NC-ND 4.0; CC-BY-NC 4.0 Nous recommandons aux auteurs de préférer la licence CC-BY 4.0, conforme aux recommandations de l'ANR. <a href="#">Plus d'information sur les licences</a>
<b>Mise en ligne sur Hal</b>	<ul style="list-style-type: none"> <li>Version finale éditeur déposable immédiatement dans une archive ouverte pour le choix de publication Gold Open Access</li> <li>Manuscrit auteur accepté déposable immédiatement et diffusible avec un embargo (6 mois en STM, 12 mois en SHS) pour le choix de publication « Subscription » - version éditeur non diffusible</li> </ul>
<b>Partage avec les pairs</b>	<a href="#">Politique de l'éditeur</a>
<b>Validation de l'éligibilité de l'auteur</b>	Utiliser de préférence l'adresse de mail institutionnelle Rennes 2 La validation se fait sur l'affiliation de l'auteur correspondant qui publie l'article dans le workflow, par l'institution ou le consortium Couperin
<b>Plus d'informations sur le site du consortium Couperin</b>	<a href="https://www.couperin.org/negociations/accords-specifiques-so/elsevier/">https://www.couperin.org/negociations/accords-specifiques-so/elsevier/</a>
<b>Plus d'informations sur le site de l'éditeur</b>	<a href="#">Pages dédiées à l'accord</a> <a href="#">Parcours Auteur</a> <a href="#">Vidéo du parcours de publication auteur</a>

### Détail du parcours de publication auteur et des choix à opérer

#### 1. Lors de la soumission de l'article

Dans le cadre du processus de soumission, une fois que l'auteur a téléchargé les fichiers du manuscrit, l'auteur correspondant fournit les détails de son affiliation.

The screenshot shows the Elsevier manuscript submission interface. A 'Edit Author Details' pop-up window is open. It contains fields for 'Your Given/First Name\*', 'Your Family/Last Name\*', 'Academic Degree(s)', 'Your E-mail Address\*', 'ORCID', 'Institution\*', and 'Country or Region'. There are also checkboxes for 'Save these changes to my user registration as well' and 'This is the corresponding author'. Arrows from the annotations point to the 'Your Given/First Name\*' field, the 'Your E-mail Address\*' field, the 'Institution\*' field, and the 'ORCID' field.

**L'auteur de correspondance** «submitting corresponding author» est celui qui fait la soumission de l'article et reste en contact avec Elsevier du début à la fin. Il fait le choix de la publication au nom du groupe d'auteurs. Il peut exceptionnellement être différent de l'auteur de correspondance indiqué dans les affiliations de l'article publié (ex: gestion du processus de soumission par un doctorant)

utiliser votre adresse mail institutionnelle Rennes 2.

Indiquer son identifiant ORCID est une bonne pratique qui facilite la découverte de l'article et son attribution au bon auteur. Il peut également aider votre institution à mieux vous identifier pour valider l'exemption des frais de publication.

Plusieurs libellés peuvent être proposés pour l'Université Rennes 2 (variations présentes dans la base d'Elsevier) mais ils sont ensuite automatiquement consolidés par l'éditeur

Au moment de la soumission, un choix indicatif de type de publication est demandé s'il s'agit d'une revue hybride, ou d'une revue non éligible à l'accord. Il n'est pas connu de l'éditeur ou de reviewer, et est modifiable par la suite.

Based on the information you have provided, these are your publishing options.  
If the journal accepts your article, you can change your mind about these options.  
Note: editors and reviewers can only see your selection after acceptance.

This is a Transformative Journal®

## Options de publication dans une revue Hybride

### Gold Open Access

Publish as an Open Access article  
Make my final published article available to everyone upon acceptance.

I am an author affiliated with the Nantes University. As there is an agreement in place between the French higher education and research Institutions consortium (CouspeM) and Elsevier to cover the APC (Article Publishing Charge) for publishing Open Access, I do not have to pay an APC if all of the following criteria are met:

- My Institution has APCs available by the time the journal accepts the article
- My Institution approves using the agreement funds to pay the APC

To pay on acceptance

Only applicable if article accepted

APC	Price
APC	EUR 3,120.00
Institutional Agreement Discount	- 3,120.00
Total	0.00

To pay (on validation)

Subscription

Publish as a subscription article  
I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of Elsevier's programs.

I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 12 months. I have additional article sharing rights outlined [here](#).

L'option à retenir dépend de votre choix et de celui de co-auteurs. L'université n'apporte pas de recommandation et il n'y a pas de conséquence financière immédiate.

Dans le choix 1 (Gold Open Access) l'avantage est de rendre l'article immédiatement accessible pour tous dans le monde, et de bénéficier d'une visibilité importante, sans frais puisque vous bénéficiez de l'accord.

Le choix 2 (publication traditionnelle) tarde la mise en accès ouvert de votre article de 12 mois (dépôt du manuscrit auteur dans Hal avec embargo). Si votre intention était de publier de manière standard, que vous n'avez pas d'obligation de diffusion en accès ouvert immédiat (en raison d'un financement ANR par exemple), cette voie évite d'encourager une stratégie commerciale qui coûte cher aux institutions (maintien de revues hybrides qui font payer 2 fois les universités, et courir un risque d'augmentation des tarifs lors de la renégociation sur la base d'un nombre croissant de publications en « Gold open access »).

Revue non éligible : pour la publication en Open Access un bon de commande sera nécessaire selon les procédures habituelles dans votre unité



These are the available publishing options.  
If the journal accepts your article, you can change your mind about these options.  
Note: editors and reviewers can only see your selection after acceptance.

## Options de publication dans Cell Press/Lancet

### Gold Open Access

Publish as an Open Access article  
Make my published article available to everyone upon acceptance.

As a corresponding author affiliated with the University of Avignon, upon validation, [the agreement between the French institutions and Elsevier](#) will cover the APC with a valid purchase order number after acceptance.

I will need to enter the valid PO number as part of the post acceptance journey. For guidance on how to collect PO number from my institution, I can refer to this [link](#).

To pay on acceptance

Only applicable if article accepted

	Price
APC	EUR 4,880.00
Institutional Agreement Discount	- 488.00
Total	0.00

To pay (on validation)

(including tax)  
EUR 4,392.00

- Indication à l'auteur qu'il devra fournir un bon de commande (en cours d'implémentation)



## 2. Après acceptation de l'article

L'auteur de correspondance reçoit un mail avec un lien

The screenshot shows the Elsevier Publishing your Article interface. On the left, there is a sidebar with orange text: "L'Auteur correspondant reçoit un courriel après acceptation, avec un lien unique pour compléter le processus et choisir les options de publication." Below that, it says "Puis, cliquez sur le 'Complete the Rights and Access form'". The main content area has a header "Test article" with fields for Corresponding author (Mr. Bharath Anandpala), E-mail address (varadhpala@elsevier.com), Journal (Infection, Disease & Health - TEST), Date of submission (03/01/19), and DOI (10.1016/j.idh.2022.09.016). Below this, a message reads: "Welcome Mr. Anandpala. To help us finalize the publication of your article please complete the publishing form(s) below. Note you will receive a confirmation e-mail after completing each form." A button "Complete the rights and access form" is visible. At the bottom, there are links for "How you can share your article", "Author rights information", and "A guide to publishing Open Access".

12

Il faut compléter le formulaire (vérifier son affiliation, indiquer le détail d'affiliation des co-auteurs, les détails du financeur le cas échéant (institution d'affiliation, ou autre financeur)

Puis il faut opérer le choix définitif de publication (cf plus haut). Pour les revues non éligibles, une case permet d'entrer le numéro de bon de commande pour dépôt de la facture sur Chorus.

- Sur la base des détails de l'affiliation, s'affichent les options de publication. L'option Accès libre (Gold OA) est suivie de l'option « Subscription ». L'auteur est informé que l'accord couvre l'APC.
- Si le/la bibliothécaire/ administrateur de l'institution rejette la demande de l'auteur sur la plateforme, nous précisons également aux auteurs qu'ils recevront une facture sans réduction.
- Il est toutefois possible de transférer la demande à un autre établissement sans la rejeter.
- Dans le cas l'auteur ne pas bénéficier de l'accord il pourra aussi choisir de changer son option de publication.

This screenshot shows the "Gold Open Access" section. It includes a radio button for "Publish as an Open Access article" and a note: "Make my published article available to everyone." Below this, a note states: "As an author affiliated with the Nantes University, upon validation, the agreement between the French higher education and research institutions consortium (Cooperis) and Elsevier may cover the Article Publishing Charge." There is also a note: "Please check with your institution regarding the open access policy." A table titled "Article Publishing Charge (APC)" shows a price of "EUR 3,120.00" and an "Institutional Agreement Discount" of "- 3,120.00", resulting in a "To pay (on validation)" of "0.00". A note at the bottom states: "If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,120.00 (ex-VAT). Within 2 weeks of receiving an invoice, you may contact Researcher Support to publish free of charge under the Subscription model." A "Cooperis and Elsevier Agreement" link is provided.

This screenshot shows the "Subscription" section. It includes a radio button for "Publish as a subscription article" and a note: "I will publish my article subscription, making my final published article immediately available to journal subscribers, and to other groups as part of Elsevier's programs." Below this, a note states: "I understand I can immediately share my article within my institution and privately with collaborators, and share my accepted manuscript publicly in my institution's repository after 5 March 2025. I have additional article sharing rights outlined here." A "Save and Continue" button is at the bottom.

En cas de choix Gold OA ou de réduction pour les revues non éligibles, la demande est soumise pour validation (vérification d'affiliation) à l'institution d'appartenance et traitée sous un délai maximum de 15 jours. En cas de refus, qui entraîne facturation, il est possible de changer de choix pour ne pas recevoir de facture, en contactant l'éditeur.  
Il est également possible de revenir sur son choix « subscription » et de bénéficier du Gold OA sans frais jusqu'au 31 janvier de l'année suivant la date d'acceptation.

Pour les articles en Gold OA il faut faire un choix de licence :

The screenshot shows a progress bar at the top with seven steps: Corresponding Author, Co-Author, Research Funders, Publishing Options, Licenses, Rights, Publishing Agreement, Review Order, and Confirmation. Step 5 (Licenses) is highlighted. Below the bar, a section titled "Select your user license" displays three options:

- CC BY 4.0 [CC-BY license is the recommended choice]  
A license to permit readers to share and adapt your article for any purpose, even commercially.  
Read more about CC BY 4.0
- CC BY-NC-ND 4.0  
A license to permit readers to share or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.  
Read more about CC BY-NC-ND 4.0
- CC BY-NC 4.0  
A license for readers to share and adapt your article for non-commercial purposes. Permission from Elsevier is required for commercial use of the article.  
Read more about CC BY-NC 4.0

On the right, a box highlights the CC BY 4.0 selection: "La licence CC-BY 4.0 préselectionnée est préconisée par les financeurs (ANR et UE). C'est la seule qui garantisse à l'auteur la possibilité de réutilisation sans frais de son travail (figures...) dans d'autres contextes".

At the bottom are "Previous" and "Save and Continue >" buttons.

L'auteur indique son statut et signe l'accord de publication en son nom et en celui de ses co-auteurs

The screenshot shows a progress bar at the top with the same seven steps as the previous screenshot. Step 6 (Rights) is highlighted. Below the bar, a section titled "Select Your Status" displays two main sections:

**Elsevier B.V.**

**Select Your Status**

I am the sole author of the manuscript  
 I am one author signing on behalf of all co-authors of the manuscript  
Please indicate which of the below applies to you:  
 We are all US Government employees and the article is public domain and therefore the 'License of publishing rights' clause does not apply  
 I am a US Government employee but some of my co-authors are not  
 I am not a US Government employee but some of my co-authors are  
 The work was performed by contractors of the US Government under contract number:

**Contract Number\***

All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted  
 Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted  
 None of the above  
 I am signing as an authorized representative and on behalf of my employer

**Signed on Behalf of Corresponding Author**

Please complete this section if you are not the corresponding author as listed above. A copy of this agreement will be sent to you and the corresponding author.

I am signing on behalf of the corresponding author

Name, job title and company (if employer representative)\*

E-mail address\*

At the bottom are "Previous" and "Save and Continue >" buttons.

1 Corresponding Author    2 Co-Author    3 Research Funders    4 Publishing Options    5 Deaccess    6 Rights    7 Publishing Agreement    8 Payment Details    9 Review Order    10 Confirmation

Elsevier B.V.

**Your Status**

- I am one author signing on behalf of all co-authors of the manuscript

**Le système présente l'accord de publication de la licence du journal.**

**L'accord de licence non exclusive pour la licence CC BY.**

**License of Publishing Rights**

I hereby grant to Elsevier B.V. an irrevocable non-exclusive license to publish, distribute and otherwise use all or any part of the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript ("the Article") in all forms and media (whether now known or later developed) in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication.

I acknowledge the importance of the integrity, authenticity and permanence of the scholarly record and agree that the version of the Article that appears or will appear in the journal embodies all value-adding publisher activities (including peer review co-ordination, copy-editing, formatting (if relevant) pagination, and online enrichment) shall be the definitive final record of published research ("the Published Journal Article").

I further acknowledge and agree that nothing in this Agreement shall be deemed to permit redundant/duplicate publication of the Article in violation of publishing ethics principles, as further described below.

**Supplemental Materials**

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

**L'auteur indique l'acceptation des Termes et Conditions**

**Author representations**

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libelous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses which conflict with the terms of this License Agreement.
- If I and/or any of my co-authors reside in Russia, Belarus, Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

**Governing Law and Jurisdiction**

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier B.V. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright>.

I have read and agree to the terms of the License Agreement.

9 February 2024      T-copyright license-v5/2017

[Previous](#)      [Accept Agreement >](#)

journal home page, nor further information on sanctions, see <https://www.elsevier.com/about/our-business/policies/trade-sanctions>.

**Author representations**

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libelous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the source in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses which conflict with the terms of this License Agreement.
- If and/or any of my co-authors reside in Russia, Belarus, Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/consent> for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

**Governing Law and Jurisdiction**

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier B.V. ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <https://www.elsevier.com/copyright>.

I have read and agree to the terms of the License Agreement.

9 February 2024      T-copyright license-v5(2017)

[Previous](#)      [Accept Agreement >](#)

**Rights and Access**

Une fois que l'auteur a cliqué sur Terminer :

- L'auteur correspondant et les coauteurs reçoivent une copie du résumé par e-mail
- L'article devient en libre accès sur ScienceDirect dans les 24 heures
- Le bibliothécaire/ administrateur de l'établissement recevra une notification de validation dans les 48 heures qui dispose ensuite de 3 semaines pour valider la demande
- Si le bibliothécaire/ administrateur approuve la demande, les coûts de l'APC seront couverts
- Si le bibliothécaire/ administrateur rejette la demande, l'auteur aura le choix de payer ou de publier en souscription gratuitement

Review Order	Total payment due
Research Funders Millman Inc. Grant number: GTI123	Price (including local VAT) <b>EUR 3,120.00</b>
Publishing Option Gold Open Access User License CC-BY 4.0	Institutional Agreement Discount <b>- 3,120.00</b>
Publishing Agreement I am the author signing on behalf of all co-authors of the manuscript and I am duly authorized to do so by all co-authors of the manuscript.	To pay (on validation) <b>0.00</b>
I may share my final published article widely in accordance with the user license I have selected. Further details in Elsevier Sharing Policy here.	
<a href="#">Checkpoints and License Agreement</a>	

6 June 2024      [Previous](#)      [Finish >](#)